[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GR1007213B - Pharmaceutical levothyroxine sodium formulas - Google Patents

Pharmaceutical levothyroxine sodium formulas

Info

Publication number
GR1007213B
GR1007213B GR20090100667A GR20090100667A GR1007213B GR 1007213 B GR1007213 B GR 1007213B GR 20090100667 A GR20090100667 A GR 20090100667A GR 20090100667 A GR20090100667 A GR 20090100667A GR 1007213 B GR1007213 B GR 1007213B
Authority
GR
Greece
Prior art keywords
formulas
levothyroxine sodium
tablets
pharmaceutical
pharmaceutical levothyroxine
Prior art date
Application number
GR20090100667A
Other languages
Greek (el)
Inventor
Ιουλια Τσετη
Original Assignee
Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε Με Δ.Τ. Uni-Pharma Abee,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε Με Δ.Τ. Uni-Pharma Abee, filed Critical Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε Με Δ.Τ. Uni-Pharma Abee,
Priority to GR20090100667A priority Critical patent/GR1007213B/en
Publication of GR1007213B publication Critical patent/GR1007213B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to new pharmaceutical levothyroxine sodium formulas in the form of tablets which formulas differentiate to other known compositions in that they contain desiccants (anhydrous magnesium sulphate and anhydrous potassium carbonate). The addition of the above mentioned dehydrators increase the stability of the levothyroxine sodium and prolongs the life time of tablets.
GR20090100667A 2009-12-07 2009-12-07 Pharmaceutical levothyroxine sodium formulas GR1007213B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GR20090100667A GR1007213B (en) 2009-12-07 2009-12-07 Pharmaceutical levothyroxine sodium formulas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20090100667A GR1007213B (en) 2009-12-07 2009-12-07 Pharmaceutical levothyroxine sodium formulas

Publications (1)

Publication Number Publication Date
GR1007213B true GR1007213B (en) 2011-03-15

Family

ID=44913588

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20090100667A GR1007213B (en) 2009-12-07 2009-12-07 Pharmaceutical levothyroxine sodium formulas

Country Status (1)

Country Link
GR (1) GR1007213B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2932963A1 (en) * 2014-04-16 2015-10-21 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable pharmaceutical dosage forms comprising Levothyroxine sodium

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2932963A1 (en) * 2014-04-16 2015-10-21 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable pharmaceutical dosage forms comprising Levothyroxine sodium
WO2015158463A1 (en) * 2014-04-16 2015-10-22 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable pharmaceutical dosage forms comprising levothyroxine sodium

Similar Documents

Publication Publication Date Title
JOP20180103B1 (en) PHARMACEUTICAL COMPOSITION of CARBETOCIN
BR112012021771A2 (en) methods of using sodium-glucose transporter inhibitors 1 and 2.
EA201290183A1 (en) BENZODIAZEPINUM INHIBITOR BROMODOMENE
EA201390793A1 (en) METHOD FOR OBTAINING A PHARMACEUTICAL COMPOSITION CONTAINING PIT
CL2011002857A1 (en) Compounds derived from phenyl or heteroaryl pyridine, aldosterone synthase inhibitors; pharmaceutical composition comprising a compound; pharmaceutical combination comprising a compound; and use of the compounds in the treatment of cardiovascular diseases.
CR20150174A (en) STERILIZED COMPOSITION THAT INCLUDES AT LEAST A Hyaluronic And Ascorbic Acid Magnesium Phosphate
CR10479A (en) VR1 BENCIMIDAZOLIC MODULARS
EA200971140A1 (en) TRIAILARY COMPOUNDS AND COMPOSITIONS CONTAINING THEM
MY166449A (en) Pharmaceutical composition of rosuvastatin calcium
MX2013000793A (en) Galacto-oligosaccharide-containing composition and a method of producing it.
BR112014009376A2 (en) compositions
EA200970132A1 (en) ANALOGUES OF MORPHINOL AND PYRROLIDINYL
HK1162354A1 (en) Improved dissolution stability of calcium carbonate tablets
BR112012021291A2 (en) dimeric inhibitors of iap.
SG158091A1 (en) Imidazoazepinone compounds
GEP20135859B (en) Stable combined pharmaceutical composition
TR200908237A2 (en) Pharmaceutical compositions containing calcium and vitamin D.
EA201001353A1 (en) GIDROBROMID IUBRADINA
EA201170101A1 (en) PHARMACEUTICAL COMPOSITIONS ROWVASTATINA CALCIUM
EA201001870A1 (en) NEW CRYSTAL SHAPES OF SODIUM CRUST TUNE
GR1007213B (en) Pharmaceutical levothyroxine sodium formulas
ATE533477T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING IRBESARTAN
TR201011148A1 (en) Levetiracetam pharmaceutical compositions.
PL401632A1 (en) Pharmaceutical composition comprising an ACE inhibitor and a calcium channel blocker, a method for its preparation and the dosage unit comprising the composition
GT200800178A (en) ASSOCIATION BETWEEN AN ANTIATEROTROMBOTIC AND AN INHIBITOR OF THE ANGIOTENSIN CONVERSION ENZYME

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20110412